Abbott expands UK reach of Libre with new Omnipod 5 integration and dual glucose-ketone sensor

Abbott has enhanced its FreeStyle Libre platform in the UK by linking it with Insulet’s Omnipod 5 and introducing innovative dual glucose-ketone sensors, broadening options for diabetics using automated insulin systems.

Abbott has expanded the reach of its FreeStyle Libre diabetes technology in the UK by linking the FreeStyle Libre 3 Plus sensor with Insulet’s Omnipod 5 automated insulin delivery system. The company said the move gives people living with type 1 diabetes another connected-care option and builds on an integration with Tandem Diabetes Care’s t:slim X2 pump that was rolled out this summer.

The latest pairing strengthens Abbott’s position in a fast-moving market for so-called hybrid closed-loop systems, which combine a continuous glucose monitor with an insulin pump that can automatically adjust insulin delivery. Abbott says its Libre platform is now compatible in the UK with Omnipod 5 using both the FreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus sensors, Tandem’s t:slim X2 with FreeStyle Libre 3 Plus, mylife Diabetes Care’s YpsoPump with FreeStyle Libre 3 Plus, and Medtronic’s MiniMed 780G system with Abbott’s Instinct sensor.

Abbott said the wider network of pump integrations means Libre is now the most connected continuous glucose monitoring technology globally, based on the number of pump users able to link with the system. The company also highlighted newer features in its portfolio, including what it described as the world’s first dual glucose-ketone sensor, which is designed to track glucose while also flagging rising ketone levels that can contribute to diabetic ketoacidosis.

For people using the technology, the appeal lies in reduced day-to-day effort and more tailored support. Graeme Scott, a 58-year-old from Angus who lives with type 1 diabetes, said the system had given him greater confidence and flexibility. Abbott’s UK diabetes chief, Julia Hammac, said the company’s aim was to broaden choice and make advanced treatment easier to access. Hilary Nathan of Breakthrough T1D welcomed the added options, saying people with type 1 diabetes need technologies that fit individual needs rather than a one-size-fits-all approach.